Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020

BACKGROUND: Suboptimal treatment upon progression may affect overall survival (OS) results in oncology randomized controlled trials (RCTs). We aim to assess the proportion of trials reporting post-progression treatment. METHODS: This cross-sectional analysis included two concurrent analyses. The fir...

Descripción completa

Detalles Bibliográficos
Autores principales: Olivier, Timothée, Haslam, Alyson, Prasad, Vinay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189952/
https://www.ncbi.nlm.nih.gov/pubmed/37198564
http://dx.doi.org/10.1186/s12885-023-10917-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189952/
https://www.ncbi.nlm.nih.gov/pubmed/37198564
http://dx.doi.org/10.1186/s12885-023-10917-z

Ejemplares similares